Tissue Regenix, a life sciences firm spun-out from Leeds University, recruits healthcare leader for push into US market.
Leeds University medtech spin-out Tissue Regenix has named healthcare industry veteran Patti Johnson to lead the company’s drive into the US market.
The appointment comes after Tissue Regenix Wound Care, the firm’s US subsidiary, signed a partnership deal with Community Tissue Services (CTS) in June. As part of the deal, Tissue Regenix will supply CTS, one of the largest tissue banks in the US, with its biological scaffolding technology, capable of enhanced healing of chronic wound conditions.
In the US, there are around 6.5 million patients with chronic wounds, with care costs in excess of $25bn. CTS distributes 230,000 grafts annually. Through the partnership with Regenix, CTS will be able to use the medtech’s dCELL product, which has seen 87% of treated patients seeing a reduction in their wounds, with 60% healing entirely.
Speaking of Johnston’s appointment, Greg Bila, president of Tissue Regenix USA, said: “Patti has a national reputation as a healthcare industry leader with a background in sales, wound management and development. Her appointment is a logical next step in our strategy to commercialise dCELL.”
